25 results
8-K
PCSA
Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
agreement it may enter into.
Processa is required to use commercially reasonable efforts, at its sole cost and expense to oversee such commercialization
8-K
PCSA
Processa Pharmaceuticals Inc
20 Aug 20
Entry into a Material Definitive Agreement
9:30am
reasonable efforts, at its sole cost and expense, in conjunction with a joint Processa-Yuhan Board to oversee such commercialization efforts, to research
8-K
EX-10.1
7enhylfkidrb 7kriz4
20 Aug 20
Entry into a Material Definitive Agreement
9:30am
8-K
EX-1.1
0ropovsnznfflmj7hx8r
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm